GlobeNewsWire
04 Sept 2026, 23:05 UTC · 4h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
3 claims · each scored for market impact
Novartis' Phase 3 HORIZON trial for pelacarsen failed to meet its primary endpoint of reducing cardiovascular events. — The clinical failure of a Phase 3 drug candidate typically removes significant future revenue potential for the developers and funders.
-0.60Royalty Pharma expects to recoup its total investment and earn a modest positive return (1.1x) on its pelacarsen/Spinraza funding agreement despite the trial failure. — This mitigates the downside for RPRX shareholders by confirming that the investment was structured to avoid a total loss.
+0.20Royalty Pharma reiterates its 2030 Portfolio Receipts target of $4.7 billion or more. — Maintaining long-term guidance suggests the pelacarsen failure does not materially impair the company's overall financial trajectory.
+0.10Which stocks this story touches
Continue reading
6 related stories
Top 3 movers · tap to explore
The Phase 3 HORIZON outcomes trial for pelacarsen failed to meet its primary endpoint.
The failure of pelacarsen means the company will not receive milestone payments from Royalty Pharma.
The company suffered a failure in the pelacarsen trial, though it expects a modest positive return due to protective structuring.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
7h ago
